Compositions comprising variant LT-B-R-IG fusion proteins
US8338376B2 · kind B2 · utility
2Cited by
37References
77Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 15, 2009 |
| Grant date | Dec 25, 2012 |
| Priority date | — |
| Expiry date | Dec 18, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to methods of treating disease with soluble inhibitors of the lymphotoxin pathway having improved properties. This invention also relates to improved LTBR-Ig fusion proteins, and pharmaceutical compositions thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.